The key performance was as follows:
- Net sales EUR 311.2 million
- Operating profit EUR 90.9 million
- Earnings per share EUR 0.47
- Equity ratio 75.4%
- ROCE 44.1%
The Board proposes a dividend of EUR 1.00 per share.
The information included in this release about the progress of the negotiations on the heart failure drug Simdax (levosimendan) are published also in a separate stock exchange release today, 6 February 2007.
To facilitate the evaluation of the new company's financial performance, Orion publishes separately a proforma review of 2006 based on the post-demerger operational structure. In the proforma review, the figures are compared to those for 2005 based on a corresponding operational structure. The proforma figures have not been audited.
The matters to be handled at the AGM on 2 April 2007 are also provided in a separate stock exchange release published today.
Orion Corporation
|
Jukka Viinanen |
Jari Karlson |
|
President and CEO |
CFO |